Recombinant SARS-CoV-2 Fusion Protein Vaccine not checked
Livzon Pharmaceutical Group Inc. · V-01 · V-01 10μg
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Appearance: creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5mL) /vial Vaccination route: intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg Immunization schedule: two doses, one each on Day 0 and 21 (+7 days), respectively. Storage condition: store at 2\~8°C protected from light Expiry date: 24 months after production date”In the company’s words, NCT05096845 on ClinicalTrials.gov
- Tested for
- COVID-19 Pandemic (4 trials), COVID19
- Main trialPhase 3
- “A Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older”In the company’s words, NCT05096845 on ClinicalTrials.gov
- Other names
- V-01 · V-01 10μg · V-01 25μg
Other drugs for COVID-19 Pandemic
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Unknown | 8 Feb 2022 | Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III | |
| Phase 3Completed | 18 Feb 2022 | Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study | |
| Phase 2Unknown | 29 Sep 2021 | Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity | |
| Phase 2Unknown | 30 Nov 2022 | Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine | |
| Phase 1Completed | 18 Feb 2022 | Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026